Journal of Clinical Oncology, Vol 16, 2007-2017, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study

HM Katzenstein, LC Bowman, GM Brodeur, PS Thorner, VV Joshi, EI Smith, AT Look, ST Rowe, MB Nash, T Holbrook, C Alvarado, PV Rao, RP Castleberry and SL Cohn
Department of Pediatrics, Northwestern University, Chicago, IL, USA.

PURPOSE: Although a high rate of spontaneous regression is observed in infants with stage D(S) neuroblastoma (NB), survival is not uniform. To determine the prognostic relevance of age at diagnosis, therapy, and tumor biology in infants with stage D(S) NB, we reviewed the Pediatric Oncology Group (POG) experience. PATIENTS AND METHODS: A review of patients diagnosed with stage D(S) NB registered on POG protocols was performed. Survival according to age at diagnosis, treatment, and tumor biology was determined. RESULTS: Between 1987 and 1996, 110 infants with stage D(S) NB had an estimated 3-year survival rate of 85% +/- 4%; survival rate was 71% +/- 8% for infants 2 months of age or younger, and 68% +/- 12%, 44% +/- 33%, and 33% +/- 19% for patients with diploid, MYCN-amplified, and unfavorable histology tumors, respectively. Survival rates were similar for patients who received adjuvant chemotherapy versus those who did not (82% +/- 5% v 93% +/- 6%, respectively; P = .187). Furthermore, there was no statistical difference in survival rate for patients who underwent complete resection of their primary tumor compared with those who underwent partial resection or biopsy only (90% +/- 5% v 78% +/- 7%, respectively; P = .083). CONCLUSION: Our review confirmed that the survival of infants with stage D(S) NB is excellent. However, subsets of patients with poor prognosis can be identified by young age and unfavorable biologic factors. More effective therapy is needed for the group of stage D(S) infants who show unfavorable clinical and biologic features.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Canete, M. Gerrard, H. Rubie, V. Castel, A. Di Cataldo, C. Munzer, R. Ladenstein, B. Brichard, J. D. Bermudez, J. Couturier, et al. Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience J. Clin. Oncol., March 1, 2009; 27(7): 1014 - 1019. [Abstract] [Full Text] [PDF]

				B. De Bernardi, M. Gerrard, L. Boni, H. Rubie, A. Canete, A. Di Cataldo, V. Castel, A. Forjaz de Lacerda, R. Ladenstein, E. Ruud, et al. Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification J. Clin. Oncol., March 1, 2009; 27(7): 1034 - 1040. [Abstract] [Full Text] [PDF]

				J. Schneiderman, W. B. London, G. M. Brodeur, R. P. Castleberry, A. T. Look, and S. L. Cohn Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group J. Clin. Oncol., February 20, 2008; 26(6): 913 - 918. [Abstract] [Full Text] [PDF]

				M. Haber, J. Smith, S. B. Bordow, C. Flemming, S. L. Cohn, W. B. London, G. M. Marshall, and M. D. Norris Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma J. Clin. Oncol., April 1, 2006; 24(10): 1546 - 1553. [Abstract] [Full Text] [PDF]

				E. F. Attiyeh, W. B. London, Y. P. Mosse, Q. Wang, C. Winter, D. Khazi, P. W. McGrady, R. C. Seeger, A. T. Look, H. Shimada, et al. Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. N. Engl. J. Med., November 24, 2005; 353(21): 2243 - 2253. [Abstract] [Full Text] [PDF]

				S. Irshad, R. B. Pedley, J. Anderson, D. S. Latchman, and V. Budhram-Mahadeo The Brn-3b Transcription Factor Regulates the Growth, Behavior, and Invasiveness of Human Neuroblastoma Cells in Vitro and in Vivo J. Biol. Chem., May 14, 2004; 279(20): 21617 - 21627. [Abstract] [Full Text] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]

				Q. Wang, G. Hii, S. Shusterman, Y. Mosse, C. L. Winter, C. Guo, H. Zhao, E. Rappaport, M. D. Hogarty, and J. M. Maris ID2 Expression Is not Associated with MYCN Amplification or Expression in Human Neuroblastomas Cancer Res., April 1, 2003; 63(7): 1631 - 1635. [Abstract] [Full Text] [PDF]

				G. A. Yanik, J. E. Levine, K. K. Matthay, J. C. Sisson, B. L. Shulkin, B. Shapiro, D. Hubers, S. Spalding, T. Braun, J. L.M. Ferrara, et al. Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma J. Clin. Oncol., April 15, 2002; 20(8): 2142 - 2149. [Abstract] [Full Text] [PDF]

				S. E. Crawford, V. Stellmach, M. Ranalli, X. Huang, L. Huang, O. Volpert, G. H. De Vries, L. P. Abramson, and N. Bouck Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity J. Cell Sci., March 14, 2002; 114(24): 4421 - 4428. [Abstract] [Full Text] [PDF]

				J. Mora, W. L. Gerald, J. Qin, and N.-K. V. Cheung Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience Oncologist, June 1, 2001; 6(3): 263 - 268. [Abstract] [Full Text] [PDF]

				A. Valent, J. Benard, B. Clausse, M. Barrois, D. Valteau-Couanet, M.-J. Terrier-Lacombe, B. Spengler, and A. Bernheim In Vivo Elimination of Acentric Double Minutes Containing Amplified MYCN from Neuroblastoma Tumor Cells Through the Formation of Micronuclei Am. J. Pathol., May 1, 2001; 158(5): 1579 - 1584. [Abstract] [Full Text] [PDF]

				S. A. Burchill, I. J. Lewis, K. R. Abrams, R. Riley, J. Imeson, A. D.J. Pearson, R. Pinkerton, and P. Selby Circulating Neuroblastoma Cells Detected by Reverse Transcriptase Polymerase Chain Reaction for Tyrosine Hydroxylase mRNA Are an Independent Poor Prognostic Indicator in Stage 4 Neuroblastoma in Children Over 1 Year J. Clin. Oncol., March 15, 2001; 19(6): 1795 - 1801. [Abstract] [Full Text] [PDF]

				T. Michigami, M. Ihara-Watanabe, M. Yamazaki, and K. Ozono Receptor Activator of Nuclear Factor {{kappa}}B Ligand (RANKL) Is a Key Molecule of Osteoclast Formation for Bone Metastasis in a Newly Developed Model of Human Neuroblastoma Cancer Res., February 1, 2001; 61(4): 1637 - 1644. [Abstract] [Full Text]

				C. Poremba, C. Scheel, B. Hero, H. Christiansen, K.-L. Schaefer, J.-i. Nakayama, F. Berthold, H. Juergens, W. Boecker, and B. Dockhorn-Dworniczak Telomerase Activity and Telomerase Subunits Gene Expression Patterns in Neuroblastoma: A Molecular and Immunohistochemical Study Establishing Prognostic Tools for Fresh-Frozen and Paraffin-Embedded Tissues J. Clin. Oncol., July 1, 2000; 18(13): 2582 - 2592. [Abstract] [Full Text] [PDF]

				J. M. Maris, M. J. Weiss, C. Guo, R. B. Gerbing, D. O. Stram, P. S. White, M. D. Hogarty, E. P. Sulman, P. M. Thompson, J. N. Lukens, et al. Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children's Cancer Group Study J. Clin. Oncol., May 9, 2000; 18(9): 1888 - 1899. [Abstract] [Full Text] [PDF]

				A. K. Sarkar and J. G. Nuchtern Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes Cancer Res., April 1, 2000; 60(7): 1908 - 1913. [Abstract] [Full Text]

				H. J. Nickerson, K. K. Matthay, R. C. Seeger, G. M. Brodeur, H. Shimada, C. Perez, J. B. Atkinson, M. Selch, R. B. Gerbing, D. O. Stram, et al. Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children’s Cancer Group Study J. Clin. Oncol., February 1, 2000; 18(3): 477 - 477. [Abstract] [Full Text] [PDF]

				K. Kawa, N. Ohnuma, M. Kaneko, K. Yamamoto, T. Etoh, H. Mugishima, M. Ohhira, J. Yokoyama, F. Bessho, T. Honna, et al. Long-Term Survivors of Advanced Neuroblastoma With MYCN Amplification: A Report of 19 Patients Surviving Disease-Free for More Than 66 Months J. Clin. Oncol., October 1, 1999; 17(10): 3216 - 3220. [Abstract] [Full Text] [PDF]

				S. L. Cohn Diagnosis and Classification of the Small Round-Cell Tumors of Childhood Am. J. Pathol., July 1, 1999; 155(1): 11 - 15. [Full Text] [PDF]

				N. Bown, S. Cotterill, M. Lastowska, S. O'Neill, A. D.J. Pearson, D. Plantaz, M. Meddeb, G. Danglot, C. Brinkschmidt, H. Christiansen, et al. Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma N. Engl. J. Med., June 24, 1999; 340(25): 1954 - 1961. [Abstract] [Full Text] [PDF]